Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Pfizer and BioNTech have entered into an agreement with Japan’s Ministry of Health, Labour and Welfare (MHLW) to provide 120 million doses of their BNT162 Covid-19 vaccine candidate.
While financial details of the deal were not divulged, the terms were said to be based on the delivery timing and the volume of doses; deliveries are planned for the first half of next year.
Based on BioNTech’s mRNA technology, the BNT162 vaccine programme is supported by Pfizer’s vaccine development and manufacturing capabilities, involving at least four vaccine candidates.